|
Hutchmed China Ltd on Wednesday said it has completed patient enrollment of Sanovo, a phase three trial of Orpathys and Tagrisso. The Hong Kong-based developer of treatments for cancer and immunological diseases said the China phase three study of the drugs is for their use as a first-line treatment in certain non-small cell lung cancer patients. It is to test patients whose tumours harbour epidermal growth factor receptor mutation and MET overexpression. The phase three trial is a blinded, randomised, controlled study in previously untreated patients. It will evaluate the efficacy and safety of Tagrisso in combination with Orpathys compared to Tagrisso alone, which is a standard-of-care treatment option for these patients. The primary endpoint of the study is progression free survival. Other endpoints include overall survival, objective response rate, duration of response, disease control rate, time to response and safety. Hutchmed said it expects to report topline results from the study in the second half of 2026. Shares in Hutchmed China were down 1.0% at 238.69 pence in London on Wednesday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
